SwePub
Sök i LIBRIS databas

  Utökad sökning

WFRF:(Blin S)
 

Sökning: WFRF:(Blin S) > Cerebrospinal fluid...

LIBRIS Formathandbok  (Information om MARC21)
FältnamnIndikatorerMetadata
00010496naa a2201033 4500
001oai:gup.ub.gu.se/280887
003SwePub
008240910s2019 | |||||||||||000 ||eng|
009oai:DiVA.org:oru-74036
009oai:prod.swepub.kib.ki.se:140850110
0247 a https://gup.ub.gu.se/publication/2808872 URI
0247 a https://doi.org/10.1016/j.jalz.2019.01.0042 DOI
0247 a https://urn.kb.se/resolve?urn=urn:nbn:se:oru:diva-740362 URI
0247 a http://kipublications.ki.se/Default.aspx?queryparsed=id:1408501102 URI
040 a (SwePub)gud (SwePub)orud (SwePub)ki
041 a eng
042 9 SwePub
072 7a ref2 swepub-contenttype
072 7a art2 swepub-publicationtype
1001 a Bos, I.u Alzheimer Centrum Limburg, Maastricht University, Maastricht, the Netherlands4 aut
2451 0a Cerebrospinal fluid biomarkers of neurodegeneration, synaptic integrity, and astroglial activation across the clinical Alzheimer's disease spectrum
264 c 2019-03-07
264 1b Wiley,c 2019
520 a Introduction: We investigated relations between amyloid-beta (A beta) status, apolipoprotein E (APOE) e4, and cognition, with cerebrospinal fluid markers of neurogranin (Ng), neurofilament light (NFL), YKL-40, and total tau (T-tau). Methods: We included 770 individuals with normal cognition, mild cognitive impairment, and Alzheimer's disease (AD)-type dementia from the EMIF-AD Multimodal Biomarker Discovery study. We tested the association of Ng, NFL, YKL-40, and T-tau with A beta status (Ab beta- vs. A beta+), clinical diagnosis APOE epsilon 4 carriership, baseline cognition, and change in cognition. Results: Ng and T-tau distinguished between A beta+ from A beta- individuals in each clinical group, whereas NFL and YKL-40 were associated with A beta+ in nondemented individuals only. APOE epsilon 4 carriership did not influence NFL, Ng, and YKL-40 in A beta+ individuals. NFL was the best predictor of cognitive decline in A beta+ individuals across the cognitive spectrum. Discussion: Axonal degeneration, synaptic dysfunction, astroglial activation, and altered tau metabolism are involved already in preclinical AD. NFL may be a useful prognostic marker. (C) 2019 the Alzheimer's Association. Published by Elsevier Inc. All rights reserved.
650 7a MEDICIN OCH HÄLSOVETENSKAPx Medicinska och farmaceutiska grundvetenskaperx Neurovetenskaper0 (SwePub)301052 hsv//swe
650 7a MEDICAL AND HEALTH SCIENCESx Basic Medicinex Neurosciences0 (SwePub)301052 hsv//eng
650 7a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Neurologi0 (SwePub)302072 hsv//swe
650 7a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Neurology0 (SwePub)302072 hsv//eng
650 7a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Geriatrik0 (SwePub)302222 hsv//swe
650 7a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Geriatrics0 (SwePub)302222 hsv//eng
650 7a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Klinisk laboratoriemedicin0 (SwePub)302232 hsv//swe
650 7a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Clinical Laboratory Medicine0 (SwePub)302232 hsv//eng
653 a Alzheimer's disease
653 a Amyloid-beta
653 a Neurofilament light
653 a Neurogranin
653 a YKL-40
653 a Cognition
653 a Cerebrospinal fluid
653 a APOE
653 a mild cognitive impairment
653 a neurofilament light
653 a neurogranin
653 a protein
653 a pathology
653 a ykl-40
653 a tau
653 a degeneration
653 a association
653 a guidelines
653 a APOE
7001 a Vos, S.u Alzheimer Centrum Limburg, Maastricht University, Maastricht, the Netherlands4 aut
7001 a Verhey, F.u Alzheimer Centrum Limburg, Maastricht University, Maastricht, the Netherlands4 aut
7001 a Scheltens, P.u Alzheimer Center, VU University Medical Center, Amsterdam, the Netherlands4 aut
7001 a Teunissen, C.u Neurochemistry Lab and Biobank, Department of Clinical Chemistry, VU University Medical Center, Amsterdam Neuroscience, Amsterdam, the Netherlands4 aut
7001 a Engelborghs, S.u Department of Neurology and Memory Clinic, Hospital Network Antwerp (ZNA) Middelheim and Hoge Beuken, Antwerp, Belgium; Reference Center for Biological Markers of Dementia (BIODEM), Institute Born-Bunge, University of Antwerp, Antwerp, Belgium4 aut
7001 a Sleegers, K.u Institute Born-Bunge, University of Antwerp, Antwerp, Belgium; Neurodegenerative Brain Diseases Group, Center for Molecular Neurology, VIB, Antwerp, Belgium4 aut
7001 a Frisoni, G.u University of Geneva, Geneva, Switzerland; IRCCS Istituto Centro San Giovanni di Dio Fatebenefratelli, Brescia, Italy4 aut
7001 a Blin, O.u Mediterranean Institute of Cognitive Neuroscience, Aix Marseille University, Marseille, France4 aut
7001 a Richardson, J. C.u Neurosciences Therapeutic Area, GlaxoSmithKline R&D, Stevenage, UK4 aut
7001 a Bordet, R.u University of Lille, Inserm, CHU Lille, Lille, France4 aut
7001 a Tsolaki, M.u 1st Department of Neurology, AHEPA University Hospital, Makedonia, Thessaloniki, Greece4 aut
7001 a Popp, J.u Geriatric Psychiatry, Department of Mental Health and Psychiatry, Geneva University Hospitals, Geneva, Switzerland; Department of Psychiatry, University Hospital of Lausanne, Lausanne, Switzerland4 aut
7001 a Peyratout, G.u Department of Psychiatry, University Hospital of Lausanne, Lausanne, Switzerland4 aut
7001 a Martinez-Lage, P.u Department of Neurology, Center for Research and Advanced Therapies, CITA-Alzheimer Foundation, San Sebastian, Spain4 aut
7001 a Tainta, M.u Department of Neurology, Center for Research and Advanced Therapies, CITA-Alzheimer Foundation, San Sebastian, Spain4 aut
7001 a Lleo, A.u Hospital de la Santa Creu i Sant Pau, Barcelona, Spain4 aut
7001 a Johannsen, P.u Danish Dementia Research Centre, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark4 aut
7001 a Freund-Levi, Yvonne,d 1956-u Department of Neurobiology, Caring Sciences and Society (NVS), Division of Clinical Geriatrics, Karolinska Institutet, Stockholm, Sweden; Department of Geriatric Medicine, Karolinska University Hospital Huddinge, Stockholm, Sweden; Department of Psychiatry Norrtälje Hospital Tiohundra, Norrtäije, Sweden4 aut0 (Swepub:oru)yfi
7001 a Frolich, L.u Department of Geriatric Psychiatry, Zentralinstitut für Seelische Gesundheit, University of Heidelberg, Mannheim, Germany4 aut
7001 a Vandenberghe, R.u University Hospital Leuven, Leuven, Belgium4 aut
7001 a Westwood, S.u University of Oxford, Oxford, United Kingdom4 aut
7001 a Dobricic, V.u Lübeck Interdisciplinary Platform for Genome Analytics, University of Lübeck, Lübeck, Germany4 aut
7001 a Barkhof, F.u Department of Radiology and Nuclear Medicine, VU University Medical Center, Amsterdam, the Netherlands; Institutes of Neurology and Healthcare Engineering, University College London, London, UK4 aut
7001 a Legido-Quigley, C.u Steno Diabetes Center, Copenhagen, Denmark; King's College London, London, UK4 aut
7001 a Bertram, L.u Lübeck Interdisciplinary Platform for Genome Analytics, University of Lübeck, Lübeck, Germany; School of Public Health, Imperial College London, London, UK; Department of Psychology, University of Oslo, Oslo, Norway4 aut
7001 a Lovestone, S.u University of Oxford, Oxford, United Kingdom4 aut
7001 a Streffer, J.u Reference Center for Biological Markers of Dementia (BIODEM), Institute Born-Bunge, University of Antwerp, Antwerp, Belgium; Early Clinial Neurology, UCB Biopharma SPRL, Braine-l'Alleud, Belgium4 aut
7001 a Andreasson, Ulf,d 1968u Gothenburg University,Göteborgs universitet,Institutionen för neurovetenskap och fysiologi, sektionen för psykiatri och neurokemi,Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry,Clinical Neurochemistry Lab, Institute of Neuroscience and Physiology, Sahlgrenska University Hospital, Mölndal, Sweden; Department of Psychiatry and Neurochemistry, University of Gothenburg, Institute of Neuroscience and Physiology, Mölndal, Sweden4 aut0 (Swepub:gu)xaulfz
7001 a Blennow, Kaj,d 1958u Gothenburg University,Göteborgs universitet,Institutionen för neurovetenskap och fysiologi, sektionen för psykiatri och neurokemi,Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry,Clinical Neurochemistry Lab, Institute of Neuroscience and Physiology, Sahlgrenska University Hospital, Mölndal, Sweden; Department of Psychiatry and Neurochemistry, University of Gothenburg, Institute of Neuroscience and Physiology, Mölndal, Sweden4 aut0 (Swepub:gu)xbleka
7001 a Zetterberg, Henrik,d 1973u Gothenburg University,Göteborgs universitet,Institutionen för neurovetenskap och fysiologi, sektionen för psykiatri och neurokemi,Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry,Clinical Neurochemistry Lab, Institute of Neuroscience and Physiology, Sahlgrenska University Hospital, Mölndal, Sweden; Department of Psychiatry and Neurochemistry, University of Gothenburg, Institute of Neuroscience and Physiology, Mölndal, Sweden; Department of Molecular Neuroscience, UCL Institute of Neurology, London, UK; UK Dementia Research Institute, London, UK4 aut0 (Swepub:gu)xzethe
7001 a Visser, P. J.u Alzheimer Centrum Limburg, Maastricht University, Maastricht, the Netherlands; Alzheimer Center, VU University Medical Center, Amsterdam, the Netherlands4 aut
7102 a Alzheimer Centrum Limburg, Maastricht University, Maastricht, the Netherlandsb Alzheimer Center, VU University Medical Center, Amsterdam, the Netherlands4 org
7730 t Alzheimers & Dementiad : Wileyg 15:5, s. 644-654q 15:5<644-654x 1552-5260x 1552-5279
8564 u https://discovery.ucl.ac.uk/10070879/3/Barkhof%20Bos%20-%20Manuscript_EMIF%20CSF%201000_FINAL%20-%20Alz%20%26%20Dem%20accepted%20version.pdf
8564 8u https://gup.ub.gu.se/publication/280887
8564 8u https://doi.org/10.1016/j.jalz.2019.01.004
8564 8u https://urn.kb.se/resolve?urn=urn:nbn:se:oru:diva-74036
8564 8u http://kipublications.ki.se/Default.aspx?queryparsed=id:140850110

Hitta via bibliotek

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy